AGENDA

Uniform Formulary Beneficiary Advisory Panel
23 June 2011 @ 0900 AM

Naval Heritage Center Theater
701 Pennsylvania Ave. NW., Washington DC 20004

- Administrative Meeting (BAP members only @ 7:30 AM-9:00 AM)
- Sign-In
- Welcome and Opening Remarks
- Public Citizen Comments
- Therapeutic Class Reviews

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations of the following drug classes during the May 2011 meeting:

- Drug Class Reviews:
  - Atypical Antipsychotics (AAPs)
  - Nasal Allergy Drugs (NADs)
    - Nasal corticosteroids
    - Nasal antihistamines
    - Nasal anticholinergic
- Designated Newly Approved Drugs:
  - Dipeptidyl Peptidase-4 Inhibitor (dpp-4)/Biguanide fixed-dose combination (FDC)—Saxagliptin/Metformin extended release tablets (Kombiglyze XR)
  - Ophthalmic-1s—Bromfenac 0.9% ophthalmic solution (Bromday)
  - Alpha Blockers for Benign Prostatic Hypertrophy—Tamsulosin/dutasteride capsules (Jalyn)
- Items for Information—
  - Dabigatran (Pradaxa) potential prior authorization
  - Co-pay changes
Panel Discussions

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.